As a whole, treatment with Upa causes CD14 + monocytes from RA patients to exhibit reduced expression of genes associated to pathogenic STM subsets, and, concurrently, to acquire the expression of genes characterizing macrophages from RA patients in remission. The gene discussed is CD14; the disease is rheumatoid arthritis.